[The effect of therapy with cytostatics and immunomodulators on mitotic pathology in Lewis tumor cells in mice].
Potapov. Iu N IuN; Krutova. T V TV; Pashkova. V S VS; Khaleev. D V DV
Key Findings
- Thymalin altered the balance of mitotic phases in tumor cells when combined with methylnitrosourea or methotrexate
- The combination increased the frequency of abnormal mitoses linked to damage of the mitotic apparatus
- Immunomodulators like thymalin can modify the cytostatic activity of anticancer agents, likely via their mechanisms of action
Practical Outcomes
- For biohackers, the result is mostly a scientific curiosity; it doesn’t provide a usable protocol, dosage, or safety data for humans. Until human trials are done, thymalin shouldn’t be added to cancer‑related regimens for performance or longevity purposes.
Summary
A mouse experiment tested the peptide thymalin alongside chemotherapy drugs and found it changes how tumor cells divide, increasing some abnormal cell divisions. This suggests thymalin can affect chemotherapy effects, but the study is early‑stage, done in mice, and doesn’t give clear guidance for human use.
Abstract
The effect of cytostatics (methylnitrosourea and methotrexate), immunomodulators (thymalin and reaferon) and their combinations on the mitotic pathology of mice Lewis tumour cells was studied. It was revealed that chemotherapy with these agents changed the interrelation between mitotic phases and somewhat enhanced the incidence of pathologic mitoses mainly connected with the damage of mitotic apparatus. Immunomodulators differently affected the cytostatic activity of antitumour agents that may be associated with their mechanisms of action.
Study Information
pubmed
1992